marches40 %Genfit shares drop 40% following the failure of a key clinical trial

Genfit plummets after clinical trial failure

Genfit shares drop 40% following the failure of a key clinical trial.

Published 6sem1 sourceImportantupdated 12h

≈ 16sSpeed

70 %

The French biopharmaceutical company had already lost 70% since the start of the year

The fact

The French biopharmaceutical company had already lost 70% since the start of the year.

Investors question the viability of its therapeutic pipeline.

Click the link to read an article on the topic:

Explore this topic

Auto-synthesis from 1 media source · identified on June 25, 2026